Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041765 | 1.00 | MTNR1A (0.51) | MTNR1AFFAR1CA2LMNASMN1; SMN2 | |
| SCHEMBL7670945 | 0.95 | MTNR1A (0.46) | MTNR1AFFAR1CA2LMNASMN1; SMN2 | |
| SCHEMBL6631863 | 0.95 | MTNR1A (0.46) | MTNR1AFFAR1CA2LMNASMN1; SMN2 | |
| SCHEMBL1043582 | 0.90 | CA2 (0.46) | MTNR1AFFAR1CA2LMNASMN1; SMN2 | |
| SCHEMBL6973466 | 0.89 | CA2 (0.57) | FFAR1CA2LMNASMN1; SMN2MAPT | |
| SCHEMBL6973472 | 0.89 | CA2 (0.57) | FFAR1CA2LMNASMN1; SMN2MAPT | |
| SCHEMBL1042426 | 0.87 | CA2 (0.43) | MTNR1AFFAR1CA2LMNASMN1; SMN2 | |
| SCHEMBL1019038 | 0.86 | FFAR1 (0.49) | FFAR1CA2LMNASMN1; SMN2MAPT | |
| SCHEMBL1018787 | 0.86 | FFAR1 (0.49) | FFAR1CA2LMNASMN1; SMN2MAPT | |
| SCHEMBL1019975 | 0.86 | FFAR1 (0.49) | FFAR1CA2LMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381600-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | Wyeth, A Corporation of the State of Delaware (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030236241-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH | 2003-12-25 | — | — | US | disclosed |
| EP-0839145-B1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2003-11-05 | — | — | EP | disclosed |
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002085896-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
| US-5935973-A | AFFINITY FOR 5-HT1A, ALPHA1, ALPHA2 AND/OR D2 RECEPTORS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS, PSYCHOSES, DYSKINESIAS, PARKINSON'S DISEASE, HYPOTENSIVE AGENTS, TOURETTE'S SYNDROME, OBSESSIVE-COMPULSIVE BEHAVIOUR, PANIC ATTACKS, SOCIAL PHOBIAS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-08-10 | — | — | US | disclosed |
| EP-0839145-A1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003071-A1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | OPRD1, DRD1, DRD2 | MTNR1A 1336/4885FFAR1 1708/4885CA2 4787/4885 |
| US-20030236241-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | OPRD1, DRD1, DRD2 | MTNR1A 1336/4885FFAR1 1708/4885CA2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.